ARIAD Pharma (ARIA) Cash Flow Statement

Click line-items for a historical chart and %

Net income (loss)	28.23M
Depreciation and amortization
Stock-based compensation	14.66M
Deferred executive compensation expense
Revaluation of warrant liability
Other current assets	1.92M
Amounts due under license agreements
Other assets	1.33M
Accounts payable	-5.78M
Accrued compensation and benefits	-7.58M
Accrued product development expenses	-3.18M
Other accrued expenses	10.11M
Other current liabilities
Deferred revenue	3.43M
Deferred executive compensation paid
Net cash provided by (used in) operating activities
Investment in property and equipment	-39.57M
Investment in intangible assets
Net cash used in investing activities
Proceeds from borrowing of long-term debt
Repayment of long-term borrowings	-4.81M
Principal payments under capital lease obligation
Proceeds from issuance of common stock pursuant to warrants
Proceeds from issuance of common stock pursuant to stock option and purchase plans	14.23M
Payment of tax withholding obligations related to stock compensation	-1.54M
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents	74.15M
Cash and cash equivalents, beginning of period	230.89M
Cash and cash equivalents, end of period	305.04M

Entities mentioned with ARIA

View All Entities